Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
29 avr. 2024 09h00 HE
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive...
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
29 avr. 2024 07h00 HE
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets...
Lexicon Pharmaceuticals to Host 2024 Investor Day
18 avr. 2024 08h00 HE
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the...
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03 avr. 2024 08h00 HE
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner,...
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
25 mars 2024 09h20 HE
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two...
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
12 mars 2024 08h00 HE
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial...
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
11 mars 2024 07h15 HE
|
Lexicon Pharmaceuticals, Inc.
Commercial launch of INPEFA® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase...
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
11 mars 2024 07h05 HE
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase...
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
11 mars 2024 07h00 HE
|
Lexicon Pharmaceuticals, Inc.
Preparations Underway for Resubmission of New Drug Application for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in Patients with Type 1 Diabetes and Chronic Kidney Disease ...
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
08 janv. 2024 07h00 HE
|
Lexicon Pharmaceuticals, Inc.
-INPEFA® Launch Positioned for Acceleration in 2024- -Clinical Data and FDA Feedback Support INPEFA Life Cycle Management Opportunity in Hypertrophic Cardiomyopathy- ...